Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Rat (Rattus) MAP2K7 Antibodies:
anti-Human MAP2K7 Antibodies:
anti-Mouse (Murine) MAP2K7 Antibodies:
Go to our pre-filtered search.
Human Monoclonal MAP2K7 Primary Antibody for ICC, FACS - ABIN969271
Yoshizawa, Hammaker, Sweeney, Boyle, Firestein: Synoviocyte innate immune responses: I. Differential regulation of interferon responses and the JNK pathway by MAPK kinases. in Journal of immunology (Baltimore, Md. : 1950) 2008
Show all 2 Pubmed References
Human Polyclonal MAP2K7 Primary Antibody for IHC, ELISA - ABIN1847618
Zhang, Wang, Man, Zhu, Bai, Wei, Liu, Liu, Wang, Gu, Wang: Reactive oxygen species generated from skeletal muscles are required for gecko tail regeneration. in Scientific reports 2017
The assessment of the interaction between GADD45beta and MKK7 and the elucidation of the recognition surfaces between DTP3 and MKK7 significantly advance the understanding of the mechanism underlying the inhibition of the GADD45beta/MKK7 interaction by DTP3 and pave the way to the design of small-molecule DTP3 analogues.
In the coBRIM phase III trial, the addition of cobimetinib, an MEK inhibitor, to vemurafenib, a BRAF inhibitor, significantly improved progression-free survival [hazard ratio (HR), 0.58; P < 0.0001] and overall survival (HR, 0.70; P = 0.005) in advanced BRAF-mutated melanoma. Here, we report on the incidence, course, and management of key adverse events (AEs) in the coBRIM study
the p.Glu116Lys rare variant in MAP2K7 predisposes its carriers to develop COPD, which would provide a useful genetic biomarker for COPD susceptibility in Chinese.
Combination BRAF and MEK inhibition has also been shown to improve overall survival in patients with V600E-mutated melanoma. Responses to therapy are often rapid, and treatment is not associated with immune-related adverse events.
Our findings indicate that GADD45 essentially suppresses the MKK7-JNK pathway and suggest that differentially expressed GADD45 family members fine-tune stress-inducible JNK activity.
The latter insight is likely to promote the production of allosteric MAP2K7 inhibitors.
MEK activation cooperates with Cdkn2a and Pten inactivation to induce melanoma
MKK7 undergoes neddylation in human breast cancer cells
In an Eastern Chinese population, carriers of MAP2K7 rs3679T variant genotypes had an increased risk of NSCLC.
Therefore, EGF is suggested to induce E-cadherin down-regulation at the transcriptional level through the MEK/ERK pathway, which might result in, at least in part, the induction of cellular morphological changes and cell migration in LoVo cells.
combined pan-RAF and MEK inhibition can overcome intrinsic and acquired resistance to single-agent RAF/MEK inhibition, supporting dual pan-RAF and MEK inhibition as a novel therapeutic strategy for BRAF- and KRAS-mutant cancers
our study suggested that black rice anthocyanins extract suppress metastasis in breast cancer cells by targeting the RAS/RAF/MAPK pathway
Crystal structures of the wild type and C218S mutant of MAP2K7 were determined. Cys218 plays a crucial role in configuring an auto-inhibition form of MAP2K7.
We found that the MKK7 p.Glu116Lys rare polymorphism was significantly associated with lung cancer risk, progression and prognosis
we explored the effects of selumetinib in combination with gefitinib in a panel of TNBC cells, in order to evaluate whether the simultaneous blockade of the EGFR and the RAS/MEK/ERK pathway might increase the antitumor activity of selumetinib in TNBC.
a widespread role for the JNK-CELF2 axis in controlling splicing during T-cell activation, including a specific role in propagating JNK signaling.
This review will focus on the science and clinical findings related to targeted therapies that inhibit BRAF or MEK as well as the immunotherapies that block the CTLA-4 or PD-1 pathways
BCR-ABL promotes PTEN downregulation through a MEK dependent pathway.
The crystal structure of JNK1 in complex with the second docking site of MKK7, was determined, revealing two different binding modes of the docking motif correlating with observations from NMR exchange spectroscopy.
In conclusion, the expression of hepatitis B virus core protein sensitized hepatocytes to TNF-alpha-induced apoptosis by disrupting the interaction between MKK7 and RACK1.
The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase specifically activates MAPK8/JNK1 and MAPK9/JNK2, and this kinase itself is phosphorylated and activated by MAP kinase kinase kinases including MAP3K1/MEKK1, MAP3K2/MEKK2,MAP3K3/MEKK5, and MAP4K2/GCK. This kinase is involved in the signal transduction mediating the cell responses to proinflammatory cytokines, and environmental stresses. Multiple alternatively spliced transcript variants encoding distinct isoforms have been found, but only one transcript variant has been supported and defined.
mitogen-activated protein kinase kinase 7
, JNK kinase 2
, JNK-activating kinase 2
, JNKK 2
, MAP kinase kinase 7
, MAPK/ERK kinase 7
, MAPKK 7
, MEK 7
, c-Jun N-terminal kinase kinase 2
, dual specificity mitogen-activated protein kinase kinase 7
, SAPK kinase 4
, stress-activated protein kinase kinase 4
, mitogen activated protein kinase kinase 7
, protein kinase, mitogen activated, kinase 7